Bolt Biotherapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Bolt Biotherapeutics has a total shareholder equity of $112.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $159.8M and $47.0M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$102.19m |
| Equity | US$112.74m |
| Total liabilities | US$47.04m |
| Total assets | US$159.78m |
Recent financial health updates
We Think Bolt Biotherapeutics (NASDAQ:BOLT) Needs To Drive Business Growth Carefully
Mar 15
Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?
May 13Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?
Dec 01We're Keeping An Eye On Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Rate
Jul 27We're Not Very Worried About Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Rate
Apr 12We Think Bolt Biotherapeutics (NASDAQ:BOLT) Can Afford To Drive Business Growth
Dec 03Recent updates
We Think Bolt Biotherapeutics (NASDAQ:BOLT) Needs To Drive Business Growth Carefully
Mar 15Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?
May 13Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?
Dec 01Bolt Biotherapeutics: A Promised Follow Up
Aug 26Bolt Biotherapeutics GAAP EPS of -$0.61 beats by $0.08, revenue of $1.39M beats by $0.89M
Aug 10We're Keeping An Eye On Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Rate
Jul 27We're Not Very Worried About Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Rate
Apr 12We Think Bolt Biotherapeutics (NASDAQ:BOLT) Can Afford To Drive Business Growth
Dec 03Bolt Biotherapeutics: Pioneering A New Class Of Immunotherapies
Aug 18We're Hopeful That Bolt Biotherapeutics (NASDAQ:BOLT) Will Use Its Cash Wisely
Aug 18Financial Position Analysis
Short Term Liabilities: BOLT's short term assets ($105.7M) exceed its short term liabilities ($20.5M).
Long Term Liabilities: BOLT's short term assets ($105.7M) exceed its long term liabilities ($26.6M).
Debt to Equity History and Analysis
Debt Level: BOLT is debt free.
Reducing Debt: BOLT had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BOLT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: BOLT has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 23.7% each year.